23rd Pharmacovigilance 2020 is a conference dedicated to the current thinking on predicting and assessing risks such as drug-induced liver injury, and the assessment of expected.
23rd Pharmacovigilance 2020 covers topics such as:
- Key regulations and pharmacovigilance system
- Predictions & updates on the global pharmacovigilance market
- Pharmacovigilance and its effect in healthcare and patient care
- Pharmacovigilance and its importance in the pharmaceutical industry expands
- Concerns with drug safety by recognizing the risks associated with pharmaceutical products and reducing the possibility of any potential harm to patients
- Demand for pharmacovigilance and consumer
- Planning pharmacovigilance and management
- Legislation and proposals for pharmaceutical drugs endorse and carry out post marketing drug tests
- A performance management strategy across the drug development lifecycle
- Concentrating on the pharmacovigilance regulatory system in the of risk management planning
- Global perspective of pharmacovigilance and risk management strategies
- The complexities of communicating and controlling the established quality risks
- Real world evidence: The evolving regulatory landscape, information and integrated usage
- Discussing about improving health outcomes and patient safety
- A new approach and towards pharmacovigilance regulations
- How real-world data is used today to evidence in major markets
- Be part of a major networking opportunity
- New regulatory guidelines and laws governing pharmacovigilance
23rd Pharmacovigilance 2020 brings together attendees from Pharmaceutical organizations Generic pharmaceutical companies Contract research organizations Patient recruitment companies Government- Department of health Non-profit organizations/ Association Consultants.
